- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders
Wave Life Sciences (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics, a biotechnology company that is building a new universe of genetic medicines using its machine learning-driven biomedical platform, today announced the formation of a collaboration to identify novel therapies to be developed by Wave …
Wave Life Sciences (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics, a biotechnology company that is building a new universe of genetic medicines using its machine learning-driven biomedical platform, today announced the formation of a collaboration to identify novel therapies to be developed by Wave for the treatment of genetic neuromuscular disorders.
As quoted in the press release:
“Wave is an industry leader in developing optimized oligonucleotides and in adopting science-based disruptive technologies,” said Brendan Frey, PhD, Scientific Founder and Chief Executive Officer of Deep Genomics. “For this reason, Wave and Deep Genomics are a good match. Wave’s efforts complement our discovery platform, which combines automation, high volume data acquisition and genome biology in a machine learning system. By working together, we aim to extend what is currently known about splicing targets in genetic neuromuscular disorders.”
“Deep Genomics is a world leader in building machine learning systems that incorporate advanced biological knowledge and data, and we are excited to use these systems for drug discovery,” said Paul Bolno, MD, MBA, Chief Executive Officer and President of Wave Life Sciences. “We believe this collaboration will enable a more profound understanding of splicing biology and illuminate new approaches to increase the size of patient populations with genetic neuromuscular disorders that may be eligible for treatment. We intend to use these new insights to expand the universe of druggable splicing targets beyond Duchenne muscular dystrophy and spinal muscular atrophy and direct our highly efficient stereopure oligonucleotides toward optimal regions or sequences within those targets.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â